Endogenous adenosine mediates the presynaptic inhibition induced by aglycemia at corticostriatal synapses.
Energy deprivation, as a result of aglycemia, leads to depression of the central synaptic transmission. Endogenous adenosine has been implicated in this depressant effect. We have studied the possible involvement of endogenous adenosine in the depression of corticostriatal excitatory transmission induced by glucose deprivation by using intracellular recordings in brain slices. After stimulation of corticostriatal fibers, EPSPs were recorded from striatal spiny neurons. Adenosine (3-300 microM) or brief periods (5-10 min) of aglycemia reduced the EPSP amplitude but did not alter the membrane potential and the resistance of the recorded cells. These inhibitory effects were not associated with an alteration of the postsynaptic sensitivity to exogenous glutamate but were coupled with an increased paired-pulse facilitation, suggesting the involvement of presynaptic mechanisms. A delayed postsynaptic membrane depolarization/inward current was detected after 15-20 min of glucose deprivation. The presynaptic inhibitory effects induced by adenosine and aglycemia were both antagonized either by the nonselective adenosine receptor antagonist caffeine (2.5 mM) or by the A1 receptor antagonists 8-cyclopentyl-1,3-dimethylxanthine (CPT, 1 microM) and 1,3-dipropyl-8-cyclopentylxanthine (CPX, 300 nM). Conversely, these antagonists affected neither the delayed membrane depolarization/inward current nor the underlying conductance increase produced by glucose deprivation. The ATP-sensitive potassium channel blockers tolbutamide (1 mM) and glipizide (100 nM) had no effect on the aglycemia-induced decrease of EPSP amplitude. Our data demonstrate that endogenous adenosine acting on A1 receptors mediates the presynaptic inhibition induced by aglycemia at corticostriatal synapses, whereas ATP-dependent potassium channels do not play a significant role in this presynaptic inhibition.
Calabresi
P
P
Clinica Neurologica, Universitá di Roma Tor Vergata, Dipartimento Sanitá, 00173 Rome, Italy.
Centonze
D
D
Pisani
A
A
Bernardi
G
G
D000241:Adenosine / Q000494:pharmacology* / Q000502:physiology*; D000818:Animals; D002110:Caffeine / Q000494:pharmacology; D002540:Cerebral Cortex / Q000502:physiology*; D003342:Corpus Striatum / Q000502:physiology*; D005071:Evoked Potentials / Q000187:drug effects; D005913:Glipizide / Q000494:pharmacology; D005947:Glucose / Q000494:pharmacology*; D018698:Glutamic Acid / Q000494:pharmacology; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D066298:In Vitro Techniques; D008564:Membrane Potentials / Q000187:drug effects / Q000502:physiology; D009474:Neurons / Q000187:drug effects / Q000502:physiology*; D026902:Potassium Channel Blockers; D058915:Purinergic P1 Receptor Antagonists; D051381:Rats; D017208:Rats, Wistar; D013569:Synapses / Q000187:drug effects / Q000502:physiology*; D013806:Theophylline / Q000031:analogs & derivatives / Q000494:pharmacology; D014044:Tolbutamide / Q000494:pharmacology; D014970:Xanthines / Q000494:pharmacology
D007004:Hypoglycemic Agents; D026902:Potassium Channel Blockers; D058915:Purinergic P1 Receptor Antagonists; D014970:Xanthines; C053907:8-cyclopentyl-1,3-dimethylxanthine; D002110:Caffeine; D018698:Glutamic Acid; D014044:Tolbutamide; C051360:1,3-dipropyl-8-cyclopentylxanthine; D013806:Theophylline; D005947:Glucose; D000241:Adenosine; D005913:Glipizide